entertainment -WSS

entertainment

author：entertainment 2025-09-27 23:54:00 - browse：22

gantenerumab Alzheimer's disease Roche — Sebastien Bozon/AFP via Getty Images

LONDON — The booming obesity market is attracting another player, as pharma giant Roche said Monday it was acquiring Carmot Therapeutics and the company’s line of weight loss drug candidates for $2.7 billion upfront.

The deal for Carmot, which is based in Berkeley, Calif., includes additional milestone payments of up to $400 million. Carmot is privately held, though it had filed paperwork last month for an initial public offering.

As part of the deal, Roche is gaining three experimental obesity medicines from Carmot, which are in Phase 1 or Phase 2 testing, as well as preclinical programs. While two are injectable treatments, one is being developed as an oral drug. They all target GLP-1 hormone receptors, while two are also designed to work via receptors for another hormone called GIP.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Dana Farber says 6 studies to be retracted and 31 corrected

focus

WSS

Testing for cancer recurrence creates a new limbo for patients

Head of FDA's diagnostics center, who led through Covid, retires

Medicare drug price lawsuits could be good politics for Biden

TikTok, Instagram influencers need more rules for drug ads

What causes osteoarthritis? Researchers study link to brain protein

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

hotspot

entertainment

leisure time

Virginia high school admissions case could be legal follow

Physician subsidies by hospitals soar in wake of No Surprises Act

As demand for Covid shots wanes, Moderna seeks its next success

Inaction leaves children at risk from dangerous chemotherapy drug

Apple is now the first public company to be valued at $3 trillion

FDA endorses new sterilization method for medical devices

Dobbs anniversary: the lost opportunity of abortion as health care

What causes osteoarthritis? Researchers study link to brain protein

BioMarin wins approval for gene therapy to treat hemophilia A

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Wikipedia

Why Sanofi got shellacked over its spinoff

Eli Lilly to pay $200M for Beam’s stake in gene

Dana Farber says 6 studies to be retracted and 31 corrected

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

To bolster infectious disease surveillance, genomics powerhouses team up

Physician subsidies by hospitals soar in wake of No Surprises Act

focus

focus

knowledge

leisure time